BioMarin Pharmaceutical Inc.BMRNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+146.1%
5Y CAGR+86.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+146.1%/yr
vs +28.8%/yr prior
5Y CAGR
+86.0%/yr
Recent acceleration
Acceleration
+117.3pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
22.2x
Strong expansion
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 198.83% |
| Q3 2025 | 15.55% |
| Q2 2025 | 12.71% |
| Q1 2025 | -22.69% |
| Q4 2024 | 5.17% |
| Q3 2024 | -3.61% |
| Q2 2024 | 16.42% |
| Q1 2024 | -17.85% |
| Q4 2023 | 59.33% |
| Q3 2023 | -16.26% |
| Q2 2023 | -2.33% |
| Q1 2023 | -14.12% |
| Q4 2022 | 13.33% |
| Q3 2022 | 10.14% |
| Q2 2022 | 1.14% |
| Q1 2022 | -10.56% |
| Q4 2021 | 18.71% |
| Q3 2021 | -0.49% |
| Q2 2021 | 5.68% |
| Q1 2021 | -10.86% |
| Q4 2020 | 8.94% |
| Q3 2020 | 2.34% |
| Q2 2020 | -6.35% |
| Q1 2020 | -0.32% |
| Q4 2019 | 10.46% |
| Q3 2019 | 5.86% |
| Q2 2019 | -0.90% |
| Q1 2019 | -1.23% |
| Q4 2018 | 10.50% |
| Q3 2018 | -3.08% |
| Q2 2018 | 10.80% |
| Q1 2018 | -13.69% |
| Q4 2017 | 22.79% |
| Q3 2017 | -9.04% |
| Q2 2017 | 19.57% |
| Q1 2017 | -16.05% |
| Q4 2016 | 20.38% |
| Q3 2016 | 8.38% |
| Q2 2016 | 4.06% |
| Q1 2016 | -7.56% |